APA (7th ed.) Citation

Motzer, R., Albiges, L., Treviño Aguirre, S., Kanesvaran, R., Centkowski, P., Reimers, M., . . . Braun, D. (2026). Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: Final results and biomarker analyses from the phase III COSMIC-313 study. Annals of Oncology, 37(6), 861. https://doi.org/10.1016/j.annonc.2026.02.011

Chicago Style (17th ed.) Citation

Motzer, R.J, et al. "Cabozantinib Plus Nivolumab and Ipilimumab in Previously Untreated, Advanced Renal Cell Carcinoma: Final Results and Biomarker Analyses from the Phase III COSMIC-313 Study." Annals of Oncology 37, no. 6 (2026): 861. https://doi.org/10.1016/j.annonc.2026.02.011.

MLA (9th ed.) Citation

Motzer, R.J, et al. "Cabozantinib Plus Nivolumab and Ipilimumab in Previously Untreated, Advanced Renal Cell Carcinoma: Final Results and Biomarker Analyses from the Phase III COSMIC-313 Study." Annals of Oncology, vol. 37, no. 6, 2026, p. 861, https://doi.org/10.1016/j.annonc.2026.02.011.